List view / Grid view
Filter the results
In this article, Dr Bruce Dezube explains why new cancer immunotherapy drugs that utilise the IL-2 pathway with lower side effects could offer more benefits compared to high-dose IL-2 treatment.
A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers. Nikki Withers spoke to Professor Carl Borrebaeck, who discusses how the researchers demonstrated the power of combining proteomics with genomics.
Regulatory T cells (Tregs) play a key role in regulating our immune system and inflammatory processes. Sangamo Therapeutics is evaluating the potential of CAR-Tregs (Tregs genetically modified with a chimeric antigen receptor, or CAR) for the development of therapies for immunological diseases, such as Crohn’s disease and multiple sclerosis, as…
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
Scientists observed that different cancers undergo the same genetic mutations at similar stages of evolution, the findings could become part of an ‘evolutionary rule book’ which would theoretically enable the prediction and prevention of cancer’s next evolutionary move.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
Computational analysis has been used by researchers to examine 66 types of cancer and identify 568 genes that drive tumour development.
Researchers have treated diffuse intrinsic pontine glioma (DIPG), a fatal childhood brain cancer, in mice by targeting two metabolic pathways.
A study has identified more than 200 genes that drive the progression of glioblastoma and which the researchers say present drug targets.